Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Updosing Schedules for ALK-Flex SQ
NCT00857779Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Feb 2009
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of amoxicillin + clavulanate in allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by ALK-Abelló. Primary endpoint: IgE-blocking factor. Started Feb 2009; status: completed.
02
Drugs
amoxicillin + clavulanate
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00857779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00857779.